The Lynx Group

January 2013, Vol 4, No 1

Atlanta, GA—The investigational agent ibrutinib, which is making news in the treatment of patients with leukemia, demonstrated “unprecedented” single-agent activity in patients with relapsed or refractory mantle-cell lymphoma (MCL), according to the lead author of an international phase 2 study that was reported at the 2012 American Society of Hematology meeting.
Read Article

Atlanta, GA—A chemotherapy-free regimen for patients with acute promyelocytic leukemia (APL) achieved a 2-year survival of almost 100% with less toxicity compared with cytotoxic regimens, according to a study reported at the 2012 American Society of Hematology (ASH) meeting.
Read Article

Atlanta, GA—The promise of regenerative medicine is exemplified by the regeneration of corneal epithelium from human limbal stem-cell culture.
Read Article

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and a common type of cancer.
Read Article

Cancer Treatment Centers of America (CTCA) in Philadelphia, PA, is the first US center to investigate the use of nanotherapy for the treatment of metastatic lung cancer.
Read Article


Empire Genomics is developing the first molecular diagnostic test for multiple myeloma (MM) using a novel genomic biomarker from Emory University that will allow providers to select the right treatments for the right patients based on their genetic profile.
Read Article

Cabozantinib (Cometriq; Exelixis) is the second drug ever to be approved by the FDA for the treatment of patients with metastatic medullary thyroid cancer.
Read Article

Using its priority review process, the FDA approved a new indication for abiraterone acetate (Zytiga; Janssen Biotech) for the treatment of patients with metastatic, castration-resistant prostate cancer (CRPC) before chemotherapy.
Read Article

The US Food and Drug Admin­istration (FDA) approved ponatinib (Iclusig; ARIAD Pharmaceuticals) under its accelerated program for the treatment of patients with chronic- phase (CP), accelerated-phase (AP), or blast-phase (BP) chronic myeloid leukemia (CML) that is resistant to or intolerant to tyrosine kinase inhibitor (TKI) therapy or to Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) that is resistant to or intolerant to TKI therapy. The recommended dose is 45 mg, taken orally once daily, with no regard to food.
Read Article

Page 3 of 4

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: